NCT05656027: Phase 3 Evaluation of the Safety and Efficacy of LNZ100 & LNZ101 for the Treatment of Presbyopia
- State
- Completed
- Phase
- Phase 3
- People
- 469 taking part
- Started
- 19 Dec 2022
- Primary completion
- 15 Dec 2023
- Arms
- Brimonidine ophthalmic solution dosed bilaterally
- Results
- Posted on the registry
- 19 Dec 2022: Trial registered
- 19 Dec 2022: Trial started
- 25 Jan 2024: Trial completed
- 25 Feb 2026: Trial results posted